Showing 20 of 84 recruiting trials for “non-hodgkin-lymphoma”
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
👨⚕️ Aibin Liang MD,Ph.D., Shanghai Tongji Hospital, Tongji University School of Medicine📍 1 site📅 Started Dec 2024View details ↗
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
👨⚕️ Jennifer Lue, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Dec 2024View details ↗
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
🏥 Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Dec 2024View details ↗
SynKIR-310 for Relapsed/Refractory B-NHL
Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
👨⚕️ Natalia Mikhailova, MD, PhD, St. Petersburg State Pavlov Medical University📍 1 site📅 Started Oct 2024View details ↗
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
👨⚕️ Natalia Mikhailova, MD, St. Petersburg State Pavlov Medical University📍 3 sites📅 Started Sep 2024View details ↗
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
RecruitingNCT06550427 ↗
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
👨⚕️ Tai-Chung Huang, Ph.D, National Taiwan University Hospital📍 1 site📅 Started Aug 2024View details ↗
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
👨⚕️ Breffni Hannon, MB BCh BAO, MMedSci, MCFP, Princess Margaret Cancer Centre📍 1 site📅 Started Jul 2024View details ↗
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
👨⚕️ Catherine THIEBLEMONT, Prof. Dr., Hôpital Saint-Louis📍 13 sites📅 Started Jun 2024View details ↗
RecruitingNCT06497452 ↗
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma
👨⚕️ Qingqing Cai, Ph D, Sun Yat-Sen University Cancer Center📍 1 site📅 Started Apr 2024View details ↗
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →